Key result
Circulating microplastics show no statistically significant difference in detection between AMI patients and controls.
Why the study?
Circulating micro- and nanoplastics have been linked to ischaemic heart disease, but detection from routine peripheral venipuncture and quality control requirements have not been established.
Can circulating microplastics be detected and chemically identified from routine peripheral venous blood in AMI patients and healthy controls using single-particle Raman microspectroscopy?
Case-Control (n=14)
Can circulating microplastics be detected and chemically identified from routine peripheral venous blood in AMI patients and healthy controls using single-particle Raman microspectroscopy?
Circulating microplastics can be successfully recovered and chemically identified from routine peripheral venous blood using single-particle Raman spectroscopy, offering a non-invasive, bedside-accessible alternative to coronary procedural sampling.
Supports microplastic detection via routine venipuncture in MI; extends coronary sampling data but leaves clinical relevance and causality open.
Circulating micro- and nanoplastics (MNPs) have been linked to ischaemic heart disease, but the clinical evidence rests on bulk, mass-based assays applied to predefined polymer panels in blood obtained during invasive coronary procedures. Whether the same phenomenon can be captured from a routine bedside venipuncture, and what quality control that requires, has not been established. We applied a digestion-filtration protocol coupled to untargeted single-particle confocal Raman microspectroscopy to pre-procedural peripheral venous blood (8.0–10.0 mL per venipuncture) from eight healthy controls and six patients with acute myocardial infarction (AMI). Particles were assigned against the Open Specy reference library at a Pearson correlation threshold of 0.80. After blank subtraction, nine particles were recovered from 147.0 mL of blood: polyethylene (n = 4), polystyrene (n = 3), ethylene–vinyl acetate (EVA, n = 1) and polyurethane (PU, n = 1). Microplastics were detected in four of six AMI patients (66.7%) and two of eight controls (25.0%) (OR 6.00, p = 0.277), with particle densities of 0.093 and 0.043 particles/mL (p = 0.152). Control prevalence closely matched the 31.8% reported for coronary sampling in the reference clinical series, indicating that peripheral blood is not an empty compartment for this measurement. Sub-threshold assignments were characterised point by point across all thirteen samples with complete spectral output: of 126 points returning a polymer below 0.80, 28 also returned a graphite reference, and on every one of those 28, the graphite match ranked higher than the polymer, without exception. We characterise this as carbonaceous procedural background, and it forms the empirical basis of the assignment threshold. No contrast reached significance with the subject as the unit of analysis, and no inference about causality or clinical risk can be drawn from a cohort of this size. The contribution of this work is methodological: it shows that circulating microplastics can be recovered and chemically identified from routine peripheral venous blood drawn before any intervention, that untargeted assignment returns polymers absent from the panels used by current clinical assays, and that single-particle spectroscopy permits blank attribution and background characterisation that mass-based methods cannot provide.
No takes yet. Share an insight, caveat, or question.
Arcos et al. (2026) conducted a case-control in Acute myocardial infarction (n=14). Circulating microplastics vs. Healthy controls was evaluated on Detection of microplastics (OR 6.00, p=0.277). Circulating microplastics were detected in routine peripheral venous blood from 66.7% of patients with acute myocardial infarction versus 25.0% of healthy controls (OR 6.00, p=0.277).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: